Patrick D. Walsh - 13 Nov 2025 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Reporting relationship: Director
Issuer ticker: ANIP
Reported as of: 13 Nov 2025
Net transaction value: -$750,904
SEC form: 4
Accepted by SEC: 17 Nov 2025, 18:01:38 UTC
Prior SEC filing: 18 Aug 2025
Next SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick D. Walsh, by attorney-in-fact Meredith W. Cook

Key filing fact

Patrick D. Walsh filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 17 Nov 2025.

Key facts

This page summarizes Patrick D. Walsh's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Nov 2025, 18:01.

Change

Previous filing in this sequence was filed on 18 Aug 2025.
Current net transaction value: -$750,904.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001720568 Primary reporting owner

Walsh Patrick D

Relationship: Director
Address: C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE
Signature: /s/ Patrick D. Walsh, by attorney-in-fact Meredith W. Cook
Signature date: 17 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIP transaction

Common Stock

Sale

Transaction value: $750,904
Shares: -8,643
Change %: -12%
Price: $86.88
Shares after: 61,405
Date: 13 Nov 2025
Ownership: Direct
Footnotes: F1

ANIP transaction

Common Stock

Gift

Transaction value: $0
Shares: -3,000
Change %: -4.9%
Price: $0.000000
Shares after: 58,405
Date: 13 Nov 2025
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were sold in multiple trades at prices ranging from $86.15 to $87.80. The price reported above reflects the weighted average sales price.

Footnote F2

This transaction reported on this Form 4 reflects a bona fide gift of Company's common stock to a donor-advised fund ("DAF") for charitable purposes. The Reporting Person retains no beneficial ownership or control over the donated securities following the contribution.